China Shipbuilding Special Gas Reports 83% H1 Revenue Growth with Net Profit Doubling as Tungsten Hexafluoride Sees Both Volume and Price Surge
nashnova research
CSSC Special Gas posted H1 revenue of RMB 1.904 billion and net profit of RMB 348 million, up 83% and 96% year-on-year — driven by a volume-and-price surge in tungsten hexafluoride — but operating cash flow turned negative, raising questions about the quality behind the headline growth.
How strong is this scorecard, really?
H1 revenue hit RMB 1.904 billion (+83% YoY); net profit reached RMB 348 million (+96%); non-GAAP net profit rose 117%.
Profit grew faster than revenue. This means → the company isn't just selling more — it's keeping a thicker margin on every yuan of sales.
Q2 alone was extraordinary: revenue RMB 1.203 billion (+129% YoY), net profit RMB 247 million (+171% YoY) — one quarter delivered 70% of the entire half-year profit.
Why is tungsten hexafluoride the real star here?
Tungsten hexafluoride — a high-purity gas used to deposit metal films during chip manufacturing — saw H1 revenue nearly triple year-on-year, rising in both volume and price.
Supply is shrinking: offshore high-purity tungsten powder is constrained; a Japanese producer halted output, widening the global gap. GF Securities noted long expansion cycles and weakening long-term contract anchors, suggesting the price upcycle will persist.
Demand is expanding: advanced AI nodes and high-stack memory (HBM, 3D NAND) keep pushing consumption higher. The global market sits in a tight balance.
In plain terms = supply fell, demand rose, prices climbed, and shipment volumes grew — all four at once. That is why profit exploded.
How much of the price hike actually reached the bottom line?
Q1 profit growth (+17%) lagged far behind revenue growth (+36%). This means → raw-material cost inflation hit margins first, before selling prices caught up.
Q2 flipped: profit growth (+171%) far exceeded revenue growth (+129%), and gross margin improved markedly.
In plain terms = Q1 was "costs moved first, prices lagged"; Q2 was "prices caught up, profit released in a burst" — the pricing cycle landed squarely in the second quarter.
Cash flow turned negative — what went wrong?
Operating cash flow swung from positive RMB 333 million a year ago to negative RMB 241 million, a 172% drop — the biggest miss in this report.
Management's explanation: heavy inventory build-up plus rising raw-material prices drove up cash outflows, while receivables grew within normal payment terms.
The balance sheet backs this up: receivables rose from RMB 502 million to RMB 950 million (+89%); inventory from RMB 337 million to RMB 657 million (+95%) — both roughly in line with the 83% revenue jump.
This means → the cash-flow swing is mainly the "cost" of rapid scaling, not a bad-debt signal — but if H2 collections don't follow deliveries, the quality of this growth will discount quickly.
The company added leverage — is the risk manageable?
Short-term borrowings went from zero to RMB 600 million; long-term borrowings from RMB 400 million to RMB 600 million — a deliberate leverage-up for liquidity.
Cash on hand remains RMB 2.583 billion; near-term debt service is not under pressure.
Total assets grew only 5.6% while revenue rose 83%, sharply improving asset turnover. This reflects a company extracting far more revenue from the same asset base — but only as long as cash flow catches up.
What else is worth watching beyond tungsten hexafluoride?
Nitrogen trifluoride H1 revenue grew ~13% YoY, with breakthroughs in both domestic and overseas markets; triflic acid products posted ~RMB 212 million in revenue, up over 40%.
The product portfolio has reached 98 items; annual capacity stands at 18,500 tonnes for nitrogen trifluoride and 2,000 tonnes for tungsten hexafluoride — both among the world's largest.
Weighted-average ROE climbed from 3.15% to 5.86%; basic EPS rose from RMB 0.34 to RMB 0.66.
R&D spending as a share of revenue fell from 5.33% to 3.55% — with the revenue base expanding so fast, whether absolute R&D investment kept pace deserves monitoring.
市场有风险，内容仅供研究参考，不构成投资建议。